These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Functional polymorphism of CTLA-4 and ICOS genes in allogeneic hematopoietic stem cell transplantation.
    Author: Wu J, Tang JL, Wu SJ, Lio HY, Yang YC.
    Journal: Clin Chim Acta; 2009 May; 403(1-2):229-33. PubMed ID: 19332044.
    Abstract:
    BACKGROUND: T cells play a critical role in alloimmune recognition and thus contribute to graft-versus-host disease (GVHD) and relapse prevention in hematopoietic stem cell transplantation (HSCT). Cytotoxic T lymphocyte antigen-4 (CTLA-4) and inducible costimulator (ICOS) are costimulatory molecules of T cell activation and their genetic variations can affect the capacity of T cells to become activated or inactivated. METHODS: We examined CTLA-4 (-318 C/T and +49 A/G) and ICOS (c.602 A/C and c.1624 C/T) genotypes in 123 patients with HSCT and their HLA-matched sibling donors, and then evaluated the impacts of the genetic polymorphisms on GVHD, disease relapse, and survival. RESULTS: By multivariate analysis, the donor CTLA-4 -318 TT genotype increased the risk of disease relapse (Hazard ratio [HR]: 5.91, 95% confidence interval [CI]: 1.17-29.79, P=0.0313). Recipients who received a graft from a donor with ICOS c.602 CC genotype had worse disease-free survival (HR: 5.97, 95% CI: 1.49-23.87, P=0.0115). Additionally, recipients with ICOS c.1624 TT genotype had worse overall survival (HR: 12.98, 95% CI: 2.58-65.35, P=0.0019). Nevertheless, CTLA-4 and ICOS genotypes were not associated with acute and chronic GVHD. CONCLUSIONS: Both donor and recipient CTLA-4 and ICOS gene polymorphisms might be of importance for the outcome of allogeneic HSCT.
    [Abstract] [Full Text] [Related] [New Search]